## **Product** Data Sheet

## Protease-Activated Receptor-1 antagonist 2

 Cat. No.:
 HY-143314

 CAS No.:
 1454588-34-1

 Molecular Formula:
  $C_{24}H_{23}F_2N_3O_2$ 

Molecular Weight: 423.46

Target: Protease Activated Receptor (PAR)

Pathway: GPCR/G Protein

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Protease-Activated Receptor-1 antagonist 2 is an orally active protease-activated receptor-1 (PAR-1) antagonist, with an IC<sub>50</sub> value of 7 nM. Protease-Activated Receptor-1 antagonist 2 has favorable pharmacokinetic properties which is useful in the research of cardiovascular disease (CVD), such as atherosclerosis and restenosis<sup>[1]</sup>.

IC<sub>50</sub> & Target IC50: 7 nM (PAR-1)<sup>[1]</sup>.

In Vivo Protease-Activated Receptor-1 antagonist 2 (Compound 14, 1 mpk i.v. dosing, rat and monkey) inhibits PAR-1 with an IC<sub>50</sub> of 7 nM<sup>[1]</sup>

Protease-Activated Receptor-1 antagonist 2 (10-50 mpk, p.o., rat) increase s both the AUC<sub>0-24 h</sub> and  $C_{max}$  in a dose-dependent manner<sup>[1]</sup>.

Protease-Activated Receptor-1 antagonist 2 doesn't elicit any prominent liver bioactivation or tissue toxicity signals up to an AUC of  $44 \, \mu M \cdot h^{[1]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat, monkey, $\log^{[1]}$						
Dosage:	i.v. (3 mpk for rat, 0.3 mpk for dog and monkey), p.o (10 mpk for rat, 1 mpk for dogs and monkey)						
Administration:	i.v., p.o (Pharmacokinetic Analysis)						
Result:	Pharmacokinetic parameters.						
	compound	FLIPR IC <sub>50</sub> (nM)	MRT (R; <sup>c</sup> D; <sup>d</sup> M <sup>e</sup> )	F% (R; <sup>f</sup> D; <sup>g</sup> M <sup>h</sup> )	predicted human MRT		
	Protease- Activated Receptor-1 antagonist 2	7	1.9; 18; 25	54; 100; 37	20-48		

REFERENCES				
	ead Optimization to Advanc	ee Protease-Activated Receptor-	l Antagonists in Early Discovery. J Med Chem.	2022 Apr 14;65(7):5575-5592.
	Tel: 609-228-6898	not been fully validated for n Fax: 609-228-5909	nedical applications. For research use on E-mail: tech@MedChemExpress.c	
			nouth Junction, NJ 08852, USA	OIII

Page 2 of 2 www.MedChemExpress.com